Curie.Bio launched on 14 February with $520m to provide $5m-$7m in seed financing per start-up, plus access to in-house expertise and external research services, to help new biopharmas generate enough preclinical data within 12-18 months and raise a series A venture capital round based on their best idea for a new drug. Co-founder Alexis Borisy said the Curie.Bio model could even help revive biopharma deal-making if start-up founders opt to sell their companies rather than raise more money.
The new venture capital firm was founded by a trio of company builders, including Borisy, who is also Curie.Bio’s operating...






